ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ABZA Abzena

15.75
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Abzena LSE:ABZA London Ordinary Share GB00BN65QN46 ORD GBP0.002
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 15.75 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Abzena PLC Abzena secures ADC manufacturing services contract (8914Y)

11/12/2017 7:00am

UK Regulatory


Abzena (LSE:ABZA)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Abzena Charts.

TIDMABZA

RNS Number : 8914Y

Abzena PLC

11 December 2017

Abzena plc

Abzena secures contract for integrated ADC manufacturing services to US biotech company

Cambridge, UK, 11 December 2017 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has entered into a Master Services Agreement with a US biotech company to provide process development and manufacturing services to progress a novel antibody-drug conjugate ("ADC") towards clinical trials.

The value of the entire process development and GMP manufacturing services exceeds $5 million, with the majority of the services to be provided within the next 12 months. The services will be carried out principally by Abzena's chemistry and biomanufacturing groups in Bristol, PA and San Diego, CA.

Abzena has worked with the US-based company for a number of years, with the relationship built around Abzena's chemistry services. Following the initial chemistry development, Abzena subsequently developed a cell line that will now be used to produce the antibody at its GMP manufacturing facility. Abzena will also conduct GMP production of the ADC payload reagent and the conjugation process to create the ADC for initial clinical study.

In entering into the Master Services Agreement with Abzena, the US biotech company has selected Abzena as its preferred chemistry services and manufacturing provider for its ADC program.

John Burt, CEO of Abzena, said: "Since the expansion of Abzena's service offering into the US with two acquisitions in 2015, we have seen a number of customer relationships expand. They are using more of our services across the Group's biology, chemistry and manufacturing capabilities.

"This latest deal further consolidates our existing relationship with our customer. Drawing on Abzena's integrated service offering, this ADC can progress through the preclinical and clinical trial process, with the ultimate goal of developing a new potential treatment."

-Ends-

Enquiries:

 
Abzena plc 
 John Burt, Chief Executive 
 Officer Julian Smith, Chief 
 Financial Officer             +44 1223 903498 
Numis (Nominated Adviser and 
 Broker) 
 Clare Terlouw / James Black   +44 20 7260 
 / Paul Gillam                  1000 
 
N+1 Singer (Joint Broker)      +44 20 7496 
 Aubrey Powell / Liz Yong       3000 
Instinctif Partners            +44 20 7457 
 Melanie Toyne Sewell / Alex    2020 
 Shaw / Deborah Bell            abzena@instinctif.com 
 

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

-- Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

   --    Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; 
   --    Cell line development for the manufacture of recombinant proteins and antibodies; 

-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

   --   Proprietary site-specific conjugation technologies and novel payloads for ADC development; and 
   --   GMP manufacturer of ADC linkers, payloads & combined linker-payloads. 

For more information, please see www.abzena.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTTMBITMBBBBIR

(END) Dow Jones Newswires

December 11, 2017 02:00 ET (07:00 GMT)

1 Year Abzena Chart

1 Year Abzena Chart

1 Month Abzena Chart

1 Month Abzena Chart

Your Recent History

Delayed Upgrade Clock